Salvinorin A is a psychoactive natural product that has been found to be a potent and selective κ opioid receptor agonist in vitro and in vivo. The activity of salvinorin A is unusual compared to other opioids such as morphine in that it mediates potent κ opioid receptor signaling yet leads to less receptor downregulation than observed with other κ agonists. Our initial chemical modifications of salvinorin A have yielded one analogue, herkinorin (1c), with high affinity at the µOR. We recently reported that 1c does not promote the recruitment of -arrestin-2 to the µOR or receptor internalization. Here we describe three new derivatives of 1c (3c, 3f, and 3i) with similar properties and one, benzamide 7b, that promotes recruitment of -arrestin-2 to the µOR and receptor internalization. When the important role µ opioid receptor regulation plays in determining physiological responsiveness to opioid narcotics is considered, µ opioids derived from salvinorin A may offer a unique template for the development of functionally selective µ opioid receptor-ligands with the ability to produce analgesia while limiting adverse side effects.
Introduction
Increasing evidence indicates that chemically distinct ligands can elicit different receptor regulation pathways. 1 For example, the opioids morphine, methadone, and fentanyl each promote µ opioid receptor (µOR) coupling to G proteins, but they differ in their ability to direct receptor trafficking. 2, 3 This may be due to differences in agonist-induced receptor conformations, resulting in different degrees of phosphorylation, arrestin recruitment, and vesicular trafficking. Such differences in µOR regulation and trafficking may be physiologically relevant as mice lacking -arrestin-2 display enhanced antinociception, decreased tolerance, and greatly diminished side effects (constipation and respiratory depression) following morphine treatment. [4] [5] [6] [7] Therefore, an opioid agonist conferring nonconventional receptor conformations may yield novel analgesics with reduced potential to produce unwanted side effects.
Currently, there are no selective pharmaceutical or biochemical inhibitors of G-protein couple receptor (GPCR) desensitization nor are there specific inhibitors of the GRKs or -arrestins. A therapeutic approach in which -arrestins or GRKs were individually inhibited might produce unwanted alterations of the function of other GPCRs. Furthermore, because arrestins regulate >1000 different GPCRs, 8, 9 it will be exceedingly difficult to produce receptor-selective effects using this approach. An alternate approach would be to selectively target µOR regulation by designing ligands that confer µOR conformations that allow for signaling yet disrupt receptor regulation.
Salvinorin A (1a, Figure 1 ) is a neoclerodane diterpene isolated from SalVia diVinorum, a member of the Lamiaceae family native to Oaxaca, Mexico. 10, 11 S. diVinorum has been used as a vision-inducing plant by the Mazatec Indians in their divination rituals for centuries. 12 Previous studies have shown that 1a is a potent and selective κ opioid receptor agonist in vitro and in vivo. [13] [14] [15] [16] [17] [18] [19] [20] Interestingly, 1a activates κ opioid receptor signaling with less receptor internalization than observed with other κ agonists. 21 These studies suggest that the κOR conformation induced by 1a binding is conducive to Gprotein mediated signal transduction but resistant to internalization-mediated regulation. Recent biochemical and site-directed mutagenesis studies indicate that 1a has a unique binding epitope at κORs. [22] [23] [24] These findings support a novel mode by which subtype selectivity for GPCR ligands is induced by a change in the topology of conserved residues within a common binding pocket. 23, 24 Our initial chemical modifications of 1a yielded several ligands, some agonists and some antagonists at µ, δ, or κ ORs. [25] [26] [27] In particular, herkinorin (1c) was identified as the first non-nitrogenous µ opioid receptor agonist and does not lead to receptor internalization under any conditions tested but, more interestingly, it does not promote the recruitment of -arrestin-2 to the µOR. 28 As part of our ongoing program to develop analgesics with reduced propensity to induce tolerance and dependence, we synthesized several analogues of 1c. These analogues were prepared to further elucidate the role of structure on µOR affinity, activity, and regulatory pathways.
Chemistry
We synthesized compounds 3d-3o, 7a, 7b, 8a, 8b, 9a, and 9b, as described in Schemes 1 and 2. Diterpene 1a was isolated from S. diVinorum and then converted to salvinorin B (1b), as described previously. 29 The reaction of 1b with the appropriate acid halide or acid under basic conditions afforded compounds 3d-3o. 30, 31 Alternately, the reaction of 1b with CBr 4 and PPh 3 afforded a mixture of 4 32 (59%) and its C2 epimer (14%). However, addition of the PPh 3 in two portions afforded almost exclusively the isomer. This method results in higher yields than previously described methods using SOBr 2 . 32 The reaction of 4 with sodium azide in DMF was unsuccessful. However, if the reaction was conducted in a mixture of acetic acid and DMF, 33 azide 5 32 was formed in 86% yield, a higher yield than previously described. 32 Interestingly, when the C2 epimer of 4 was subjected to identical conditions, azide 5 was also formed. Reduction of 5 using Zn metal and NH 4 Cl 34 afforded amine 6 35 in 36% yield. Staudinger reduction (PPh 3 , H 2 O) 36 of 5 was also attempted but led mainly to decomposition of starting material. 35 The treatment of amine 6 with acetic anhydride or benzoyl chloride under basic conditions and in the presence of a catalytic amount of DMAP afforded amides 7a 32, 35 and 7b, respectively. The reaction of amine 6 with methanesulfonyl chloride or benzenesulfonyl chloride using similar conditions afforded 8a and 8b. Finally, the reaction of the potassium salt of thioacetic acid or thiobenzoic acid with 4 gave 9a 32, 37 and 9b, respectively.
Results
Newly synthesized compounds 3d-3o, 7b, 8a, 8b, and 9b were then evaluated for affinity at opioid receptors using methodology previously described (Table 1) . 38 These analogues were prepared to give insight as to the nature of the high affinity and selectivity of 1a and 1c for κ and µ receptors, respectively. Recently, we investigated the effects of the addition of a bromo group to 1c (i.e., 3a-3c). 30 It was found that substitution of the bromo group in the 4-position (3c) retained high affinity at µ receptors. This modification also increased µ/κ selectivity compared to 1c. Given the clear effects of ring substitution, we sought to probe additional modifications of the benzene ring.
The addition of a 2-methoxy group (3d) decreased affinity for µ receptors over 130-fold compared to 1c (K i ) 1640 vs 12 nM). Introduction of a methoxy group in the 3-position of the benzene ring (3e) also decreased affinity for µORs and κORs compared to 1c (K i ) 30 vs 12 nM and K i ) 550 vs 90 nM, respectively). This modification, however, increased affinity 55-fold for µORs compared to 3d (K i ) 30 vs 1640 nM) and improved selectivity for µORs over κORs compared to 1c (µ/κ ) 0.05 vs µ/κ ) 0.13). The presence of a 4-methoxy group (3f) leads to an approximately 6-fold decrease in affinity (K i ) 70 vs 12 nM) and similar selectivity (µ/κ ) 0.12 vs µ/κ ) 0.13) for µORs compared to 1c. This observation and our previous finding that 3c has equal affinity when compared to 1c 30 suggest that an electron-withdrawing group in the 4-position is more favorable for µOR affinity.
The introduction of a 2-nitro group (3g) decreased affinity for µORs over 600-fold compared to 1c (K i ) 7550 vs 12 nM). This modification was better tolerated at κORs where only a 10-fold loss in affinity was observed (K i ) 900 vs 90 nM). This result, coupled with those observed for 3a, 3d, and 3g, would indicate that factors other than electronics are likely involved in the binding of 2-position analogues. Substitution of a 3-nitro group (3h) abolished affinity at µORs (K i > 10000) and decreased affinity approximately 10-fold at κORs compared to 1c (K i ) 800 vs 90 nM). Finally, a 4-nitro group (3i) was also explored. This modification decreased affinity over 20-fold for µORs and over 6-fold for κORs compared to 1c (K i ) 260 vs 12 nM and K i ) 570 vs 90 nM, respectively). This result, coupled with those observed for 3c and 3f, would indicate that factors other than the strength of the electron withdrawing group are likely involved in the binding of 4-position analogues.
We then sought to further explore the size requirements for the aromatic substituent. First, we annulated an additional benzene ring onto the 2 and 3 positions (3j). 31 This modification resulted in a roughly 1000-fold loss of affinity at µOR compared to 1c (K i > 10000 vs 12 nM). This change, however, was better tolerated at κORs with roughly a 5-fold loss in affinity compared to 1c (K i ) 410 vs 90 nM). This is interesting given the observation that replacement of the acetoxy group in 1 with an ]IOXY) or the possibility of misidentification because these compounds were not rigorously evaluated for purity. 31 Annulation of the benzene ring into the 3 and 4 positions (3k) reduced affinity at µORs approximately 10-fold compared to 1c (K i ) 180 vs 12 nM). This modification also decreased affinity for κORs greater than 50-fold (K i ) 5490 vs 90 nM). This suggests that a ,γ-annulated system increases selectivity for µORs over κORs. To probe this, we prepared 2-benzofuran 3l as an analogue that possesses a ,γ-annulated system. Somewhat surprisingly, 3l had equal affinity at µORs compared to 1c (K i ) 10 vs 12 nM). However, it retained selectivity for µORs over κORs. Previously, we showed that bioisosteric replacement of the benzene ring with a 2-thiophene (3m) retained affinity at µORs. 30 We were curious if the point of attachment might play a role in its affinity. To probe this, we synthesized the corresponding 3-thiophene (3n). Compound 3n had similar affinity to 1c for µORs and κORs (K i ) 10 vs 12 nM and K i ) 80 vs 90 nM, respectively), indicating that the point of attachment on the thiophene ring does not play a role in µOR binding. This change, however, increases affinity 3-fold for κORs (K i ) 80 vs 260 nM). Finally, we sought to further confirm the role of the aromatic moiety in the selectivity of 1c.
To address this, we prepared cyclohexyl analogue (3o). As expected, 3o had reduced affinity for µORs and κORs compared to 1c (K i ) 1030 vs 12 nM and K i ) 2010 vs 90 nM, respectively). This change also decreased selectivity for µORs over κORs (µ/κ ) 0.5 vs µ/κ ) 0.13).
While our studies were in progress, several groups reported the effects of bioisosteric replacement of the 2-acetoxy group in 1a with an acetamido group (7a). 32, 35 Consistent with those reports, we found this change resulted in a loss in affinity at κ receptors (K i ) 30 vs 1.9 nM). However, 7a was found to have affinity for µORs (K i ) 4180 nM). Given our previous finding that introduction of a benzene ring increases µ affinity, 25 we synthesized benzamide 7b. As expected, introduction of the benzene ring resulted in a decreased affinity at κ receptors and increased affinity at µ receptors. To our delight, 7b has 4-fold higher affinity than 1c (K i ) 3.1 vs 12 nM) and is more selective for µ receptors over κ receptors (κ/µ ) 0.0004 vs κ/µ ) 0.13. To further explore these developments, we synthesized sulfonamides 8a and 8b.
Previously, we showed that the addition of a methanesulfonyl group retained high affinity and activity at κORs. 25 The replacement of the acetamido group with a methanesulfonylamino group (8a) decreased affinity approximately 9-fold for κORs compared to 7a (K i ) 260 vs 30 nM). This change also abolished affinity for µORs (K i > 10000 nM). The addition of a benzene ring to 8a (8b) decreased affinity approximately 5-fold for κORs (K i ) 1400 vs 260 nM). The loss of affinity at κORs may be due to the increased ionizability of a sulfonamide compared to a sulfonyl ester. Recently, it has been shown that a tertiary amide has higher affinity for κORs than a secondary amide. 35 This data would seem to confirm this observation, as well as, our previous finding that sulfonyl esters of 1a are not binding in an identical manner to alkyl esters. 30 Finally, we probed the replacement of the 2-acetoxy group with a 2-acetylthio group. As seen previously, 37 this change resulted in a slight reduction in affinity at κ receptors (K i ) 5.7 vs 1.9 nM). However, 9a was found to have low affinity for µORs (K i ) 4370 nM). The addition of a benzene ring to 9a (9b) lead to an increase in affinity at µORs (K i ) 290 vs 4370 nM). However, this change lead to a 24-fold decrease in affinity compared to 1c, indicating an ester or amide linkage is preferential for binding at µORs.
To test the hypothesis that µ opioids derived from 1a have functional activity at opioid receptors, several analogues were then evaluated in a [
35 S]GTP-γ-S assay (Table 2) . 39, 40 The introduction of a 4-bromo substituent (3c) resulted in an approximately 10-fold decrease in activity compared to 1c (EC 50 ) 4890 vs 500 nM). This modification also reduced the efficacy compared to 1c (E max ) 108 vs 130), but 3c is just as efficacious as DAMGO (E max ) 108 vs 100). The presence of a 3-methoxy group (3e) resulted in an approximately 3-fold loss in activity at µORs compared to 1c (EC 50 ) 1670 vs 500 nM). A similar effect was seen at κORs. Interestingly, 3e is not as efficacious as 1c (E max ) 72 vs 130) and appears to be a partial agonist when compared to DAMGO (E max ) 72 vs 100). A 4-methoxy group (3f) had similar activity compared to 1c (EC 50 ) 830 vs 500 nM). However, 3f is not as efficacious at µORs as 1c (E max ) 94 vs 130) but is approximately as efficacious as DAMGO (E max ) 94 vs 100). A 4-nitro group (3i) decreased activity at µORs approximately 3-fold compared to 1c (EC 50 ) 1370 vs 500 nM). This change, however, resulted in a large decrease in efficacy compared to 1c and DAMGO (E max ) 46 vs 130 and E max ) 46 vs 100).
Substitution of the benzene ring in 1c with a 2-benzofuran (3l) resulted in an approximately 3-fold loss in activity and decreased efficacy at µORs compared to 1c (EC 50 ) 1680 vs 500 nM and E max ) 104 vs 130). However, 3l is still a full agonist when compared to DAMGO (E max ) 104 vs 100). Benzofuran 3l had similar activity at κORs compared to 1c (EC 50 ) 1120 vs 1320 nM). Strikingly, 3l was less efficacious as an agonist at κORs compared to 1a (E max ) 109 vs 140), but more efficacious than U50,488H (E max ) 109 vs 100). Bioisosteric replacement of the benzene ring in 1c with a 2-thiophene (3m) reduced activity and efficacy at µORs compared to 1c (EC 50 ) 1150 vs 500 nM and E max ) 95 vs 130). Substitution of a 3-thiophene (3n) had little effect on activity at µORs (EC 50 ) 690 nM vs 500 nM) and decreased efficacy (E max ) 108 vs 130). Compound 3n, however, is roughly as efficacious as DAMGO (E max ) 108 vs 100) at µORs.
Replacement of the 2-acetoxy group in 1a with a 2-acetamido group (7a) resulted in a 3-fold loss in activity at κORs compared to 1a (EC 50 ) 120 vs 40 nM). This change, however, had little effect on efficacy (E max ) 108 vs 120). Replacement of the 2-benzoyloxy group in 1c with a 2-benzoylamino group (7b) resulted in a slight increase in activity and no change in efficacy (EC 50 ) 360 vs 500 nM and E max ) 134 vs 130).
To better understand the role of drug structure on µOR regulation pathways, we examined the ability of 3c, 3f, 3i, and 7b to induce -arrestin-2-GFP translocation HEK-293 cells ( Figure 2 ). The effects of DAMGO, morphine, and 1c are shown for comparison.
3,28 DAMGO induces robust translocation of arr2-GFP to the plasma membrane. Morphine, however, can only induce translocation when GRK2 is overexpressed. Compounds 3c, 3f, and 3i, like 1c, are unable to induce robust arr2-GFP translocation to the plasma membrane even in the presence of GRK2 overexpression. Amide 7b induces robust arr2-GFP translocation under both conditions.
To further support the conclusion that µ opioids derived from 1a have altered receptor regulation, we examined the ability of 3c, 3f, 3i, and 7b to induce µOR-YFP internalization in HEK-293 cells ( Figure 3 ). The effects of DAMGO, morphine, and 1c are shown for comparison.
3,28 DAMGO induces robust internalization of µOR-YFP. Morphine, however, can only induce µOR-YFP internalization when GRK2 is overexpressed. Unlike DAMGO and morphine and similar to 1c, 3c, 3f, and 3i are unable to induce robust µOR-YFP internalization even in To further assess agonist activity in parallel with the current studies, we used the phosphorylation of the downstream MAP kinases (ERK1/ERK2) as an indicator of receptor activation. Compounds 3c, 3f, 3i, and 7b were examined for their ability to activate ERK in hµOR-CHO cells. In Figure 4 , 3c, 3f, 3i, and 7b are similar to DAMGO in that they are able to induce a µOR1-mediated, dose-dependent increase in ERK phosphorylation that is blocked by naloxone. 28 Taken together, these data indicate that 3c, 3f, and 3i are able to induce receptor conformations that are able to activate both G protein coupling and MAP kinase activation pathways, yet have unique properties compared to the morphine or DAMGO bound µOR rendering the receptor resistant to -arrestin interactions or internalization. Amide 7b appears to induce receptor conformations that are different than other derivatives of 1c and produces effects similar to other opioids such as DAMGO.
Discussion
Our results indicate that the structure-activity relationships for affinity and activity at µ opioid receptors are not identical to those for receptor regulation. Addition of substituents to the aromatic ring of 1c results in agonists and partial agonists at µORs and similar receptor regulation to 1c. These changes do not affect the unique receptor regulation properties of 1c. Analogues 3c, 3f, 3i are unable to induce robust arr2-GFP translocation and µOR-YFP internalization even in the presence of GRK2 overexpression in HEK-293 cells. Replacement of the ester linkage in 1c with an amide linkage (7b) increases affinity at µORs compared to 1c. Amide 7b has been identified as the most potent neoclerodane µ agonist described to date. However, this change promotes -arrestin translocation and receptor internalization in HEK-293 cells. The discovery of two compounds with nearly identical chemical structure and similar binding affinity and efficacies that elicit differential signaling at the cellular level would suggest that not only receptor conformation but also ligand structure contribute to signaling events. Future studies of the effect of chemical alterations of 1c on the activation of cellular pathways may serve as a basis for the development of compounds that can selectively activate or block -arrestin-receptor interactions may determine specific physiological responses.
The differences in affinity and receptor regulation between 1c and 7b are interesting. One potential explanation is that these two molecules, while very similar in structure are not binding in an identical manner at the µOR. This type of phenomenon has been seen previously with other opioids. 41 Another explanation is that the benzene rings in 1c and 7b may have different orientations relative to the A ring of the salvinorin core. X-ray crystallographic studies 26, 30 indicate that the benzene ring in 1c is out of the plane of the A ring of the salvinorin core. Preliminary molecular modeling indicates that the benzene ring in 7b is in the plane of the A ring. This orientation of 7b may be responsible for the increased affinity and activity at µORs compared to 1c. However, the out of the plane orientation of the benzene ring in 1c and esters 3c, 3f, and 3i may be required for the lack of the -arrestin translocation and receptor internalization. Conformationally constrained analogues will need to be prepared to further delineate the role of the benzene ring on affinity, activity, and receptor regulation pathways.
An alternate explanation for the differences seen in affinity and receptor regulation is that ester 1c hydrolyzes too rapidly in media to cause internalization and other chronic effects. Amide 7b would be expected to be more stable in serum, as recently shown for 7a. 42 Additional stability studies of 1c and 7b will be necessary to further investigate the role of metabolism in the differences seen in receptor regulation pathways. However, 1b, the likely metabolism product of ester 1c, has no affinity for µORs (K i > 10000 nM), 43 and after 30 min, 1c still produces a 3.5-fold increase in ERK phosphorylation, demonstrating a persisting agonistic activity. 28 Moreover, cells treated with DAMGO will internalize the µOR in approximately 10-15 min, therefore, the compound, which is still active at 30 min in the ERK activation assay, should be sufficiently potent to induce internalization. Furthermore, chronic treatment of 1c produces desensitization in cells, suggesting that it is active long enough to induce some yet undescribed mode of receptor desensitization. 44 The molecular basis for the unique signaling properties of 1c is not clear at this time. A likely explanation is that they are the result of a unique binding mode at the µOR relative to other opioids. Most nonpeptide opioid ligands, which contain a basic nitrogen atom, interact with aspartate 147 in TM III. 45 Given the structure of 1c, this interaction is unlikely. This explanation is further supported by recent studies, indicating that 1a utilizes unique residues in binding to κORs. [22] [23] [24] Ester 1c and related analogues may have a similar mode of binding at µORs. The exact nature of the interaction of 1c with the µOR will have to be confirmed through site-directed mutagenesis and/or affinity labeling experiments.
With regards to chemical structure, 1a and 1c have an interesting structural motif for GPCR ligands. The neoclerodane nucleus is not considered to be a priVileged structure, which is defined as a selected substructure that is able to provide high- affinity ligands for more than one type of receptor. 46, 47 However, natural products, such as 1a, can be viewed as a population of privileged structures selected by evolutionary pressures to interact with a wide variety of proteins and other biological targets for specific purposes. 48 Finding additional molecules that have unique receptor regulation pathways for GPCRs may require examining additional natural products or natural productlike libraries. 49 The life cycle of a GPCR is to reside at the cell surface and, upon activation, become phosphorylated, desensitized, internalized, and then either degraded or recycled. While internalized, the GPCR may also take part in activating signaling cascades. 50, 51 Usual drug discovery efforts for GPCRs are to develop agonists, antagonists, or inverse agonists for the GPCR of interest. In our case, this is the µ opioid receptor. Our results illustrate a novel drug discovery strategy that seeks to develop a series of compounds that retain signaling properties at a GPCR but avoid typical regulation pathways. This has a clear impact on the development of novel opioids with reduced side effects and GPCR drug discovery because this finding illustrates the ability of selecting or designing novel agents that differentially activate regulation pathways of a single receptor. This has the potential to optimize therapeutic action in vivo by alleviating unwanted side effects.
Experimental Section
General Methods. Unless otherwise indicated, all reagents were purchased from commercial suppliers and are used without further purification. All melting points were determined on a ThomasHoover capillary melting apparatus and are uncorrected. The 1 H NMR spectra were recorded at 300 MHz on a Bruker Avance-300 spectrometer using CDCl 3 as solvent, δ values in ppm (TMS as internal standard), and J (Hz) assignments of 1 H resonance coupling. Thin-layer chromatography (TLC) was performed on 0.25 mm plates Analtech GHLF silica gel plates using n-hexanes/EtOAc, 1:1 as the solvent system. Spots on TLC visualized with vanillin/H 2 SO 4 in ethanol. Column chromatography was performed with silica gel (32-63 µ particle size) from Bodman Industries (Atlanta, GA). Analytical HPLC was carried out on an Agilent 1100 Series Capillary HPLC system with diode array detection at 254.8 nm on an Agilent Eclipse XDB-C18 column (4.6 × 150 mm, 5 µm) with isocratic elution in 70% CH 3 CN/30% H 2 O at a flow rate of 5.0 mL/min. General Procedure A. A solution of 1b (1 equiv), appropriate acid chloride (1-3 equiv), NEt 3 (3 equiv), and a catalytic amount of DMAP in CH 2 Cl 2 was stirred at room temperature. Absolute MeOH was added and the solvent was removed under reduced pressure. CH 2 Cl 2 was added to the residue and the solution was washed with 10% HCl (3 × 20 mL) and saturated NaCl (3 × 20 mL) and dried (Na 2 SO 4 ). Removal of the solvent under reduced pressure afforded a crude solvent that was purified by column chromatography (eluent: n-hexanes/EtOAc) to yield the desired compound. (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(4-Bromobenzoyloxy)-2-(3-furanyl)-dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho-[2,1-c (
2S,4aR,6aR,7R,9S,10aS,10bR)-9-(2-Methoxybenzoyloxy)-2-(3-furanyl)-dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c]pyran-7-carboxylic Acid Methyl Ester (3d).
Compound 3d was synthesized from 1b using general procedure A and 2-anisoyl chloride to afford 0.010 g (14%) as a white solid, mp 105-107°C. 15 (s, 3H), 1.48   (s, 3H), 1.64 (m, 3H), 1.83 (dd, J ) 2.7, 11.7 Hz, 1H), 2.15 (m,  2H), 2.27 (s, 1H), 2.40 (m, 2H), 2.55 (dd, J ) 5.4, 12.3 Hz, 1H),  2.83 (dd, J ) 3.6, 13.2 Hz, 1H), 3.75 (s, 3H), 5.42 (dd, J ) furanyl)-dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c] Benzofuran-2-carboxylic Acid (2S,4aR,6aR,7R,9S,10aS,10bR)-7-Carbomethoxy-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c] pyran-9-yl Ester (3l). A solution of 1b (0.10 g, 0.26 mmol), benzofuran 2-carboxylic acid (0.08 mg, 0.51 mmol), HOBT (0.07 g, 0.51 mmol), and EDCI (0.120 g, 0.64 mmol) in CH 2 Cl 2 (20 mL) was stirred at room temperature for 4 d. The mixture was washed with 2 N HCl (3 × 15 mL), saturated NaHCO 3 (3 × 15 mL), and H 2 O (3 × 15 mL) and dried (Na 2 SO 4 ). Removal of the solvent under reduced pressure afforded a crude product that was purified by column chromatography (eluent: n-hexanes/EtOAc, 1:1) to afford 0.05 g of 1b and 0.016 g (22%) 19 (s, 3H), 1.48 (s, 3H), 1.64 (m, 3H), 1.84 (dd, J ) 19 (m, 2H), 2.28 (s, 1H), 2.60 (m, 3H), 2.86 (1H, dd,  J -2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c]pyran-9-yl Ester (3m) . Compound 3m was synthesized from 1b using general procedure A and 3-thiophenoyl chloride to afford 0.056 g (44%) as a white solid, mp 211-212°C. 2S,4aR,6aR,7R,9S,10aS,10bR)-9-(1-Cyclohexanecarbonyloxy)-2-(3-furanyl)-dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c] pyran-7-carboxylic Acid Methyl Ester (3o). Compound 3o was synthesized from 1b using general procedure A and cyclohexane carbonyl chloride to afford 0.091 g (71%) as a white solid, mp 104-107°C. 1 2S,4aR,6aR,7R,9S,10aS,10bR)-9-(Acetylamino)-2-(3-furanyl)-dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c] pyran-7-carboxylic Acid Methyl Ester (7a). Compound 7a was prepared from 6 using a method similar to that previously described 35 to afford 0.04 g (58%) as a white solid, mp 222-224°C (lit. 32 137-138°C; EtOAc/n-hexanes). The 1 H NMR spectra was in agreement with that previously reported. 35 , and a catalytic amount of DMAP in CH 2 Cl 2 (40 mL) was stirred at room temperature for 18 h. Absolute MeOH was then added and the solution was washed with 10% HCl (3 × 25 mL) and saturated NaCl (2 × 25 mL), dried (Na 2 SO 4 ), filtered, and concentrated under reduced pressure to yield a crude solid. The solid was purified by flash column chromatography (eluent: n-hexanes/EtOAc, 1:1). Removal of the solvent under reduced pressure gave 0.11 g (97%) of 8b as a white solid, mp 271-273°C (EtOAc/n-hexanes). 1 2-(3-furanyl)-dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c] pyran-7-carboxylic Acid Methyl Ester (9b). A solution of 4 (0.10 g, 0.22 mmol) and the potassium salt of thiobenzoic acid (0.194 g, 1.10 mmol) was stirred in acetonitrile at room temperature for 3 h. Solvent was removed under reduced pressure and it was then redissolved in DCM (30 mL). The DCM solution was washed with H 2 O (3 × 30 mL) and saturated NaCl (2 × 30 mL) and dried (Na 2 SO 4 43, 52, 53 Recombinant CHO cells (hMOR-CHO, hDOR-CHO, and hKOR-CHO) were produced by stable transfection with the respective human opioid receptor cDNA and provided by Dr. Larry Toll (SRI International, CA).
2S,4aR,6aR,7R,9S,10aS,10bR)-9-(3-Nitrobenzoyloxy)-2-(3-
-Arrestin-2 Translocation. HEK-293 cells stably expressing the µ opioid receptor (∼1000 fmol/mg membrane protein) were transiently transfected with 2 µg of -arrestin-2 tagged on the C-terminus with Green Fluorescent Protein ( arr2-GFP) and 1.5 µg G-protein receptor kinase 2 (GRK2). Experiments were also done in HEK-293 cells transiently transfected with MOR1. After incubation at 37°C for 24 to 36 h, cells were serum-starved for 30 min. Basal arr2-GFP images were obtained, followed by drug treatment for 10 min. Drugs included DAMGO (1 µM), morphine (10 µM), and 1c and its derivatives (10 µM). Cells were monitored each minute throughout the 10 min drug treatment. Representative cells at 5 min are shown. Images were taken using an Olympus Fluoview 300 confocal microscope and Olympus Fluoview imaging software version 4.3.
MOR-YFP Internalization. HEK-293 cells stably expressing MOR1 tagged with Yellow Fluorescent Protein at the C-terminus (MOR1-YFP) were transiently transfected with GRK2. After incubation at 37°C for 24 to 36 h, cells were serum-starved for 30 min. Basal MOR1-YFP images were obtained, followed by drug treatment for 2 h. Drugs included DAMGO (1 µM), morphine (10 µM), and 1c and its derivatives (10 µM). Cells were monitored every 15 min throughout the 2 h drug treatment. In some experiments, cells were left to incubate at 37°C during the hour treatment time, and this did not result in different internalization profiles. Representative cells at 60 min are shown. Images were taken using the Olympus 300 confocal microscope and Olympus Fluoview imaging software version 4.3.
ERK Activation. CHO cells stably expressing the human MOR1 (∼800 fmol/mg membrane protein) were serum-starved for 30 min at 37°C. Cells were treated with 1c or derivative for 10 min. Where indicated, naloxone was included during serum-starvation and drug treatment. After washing with PBS on ice, cells were collected in lysis buffer (20 mM Tris HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% NP-40, 0.25% dioxycholate, 1 mM sodium orthovanedate, 1 mM PMSF, 1 mM NaF, and protease inhibitor cocktail (Roche)) and centrifuged at 20000 × g for 30 min. Supernatants were quantified using Bio-Rad D c protein assay and diluted to equal concentrations with 4 × XT sample buffer (BioRad; 62.5 mM Tris-HCl, pH 6.8, 25% glycerol, 2% SDS, 0.01% bromophenol blue) with 5% -mercaptoethanol and boiled at 95°C for 3 min. Samples were subjected to SDS-PAGE and transferred to PVDF membranes. Blots were first probed with an antibody specific to total ERK1/2 (cell signaling; 1:1000). Blots were stripped and reblotted for Phospho-ERK (Tyr204; Santa Cruz; 1:2000). Bands were detected using secondary antibodies (Amersham; antirabbit IgG 1:2000 and antimouse IgG 1:5000, respectively) conjugated to horseradish peroxidase and Supersignal West Pico Chemiluminescent Substrate (Pierce). Densitometric analysis was performed on Kodak 1D imaging software. Phospho-ERK bands were normalized to corresponding total ERK bands. Statistical analysis was performed using GraphPad Prism software.
Statistics. Statistical analyses were performed using Prism software (GraphPad Software), and the specific tests used are presented in the figure legends.
